Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Prof. Éric Vivier Receives the 2026 William B. Coley Award
The Cancer Research Institute (CRI) has awarded the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology to Prof. Éric Vivier, holder of the Natural Killer (NK) Cell Chair of the Fondation Gustave Roussy. This distinction, one of the most prestigious in cancer immunology, recognizes his body of work, which has profoundly transformed the understanding of antitumor immunity and paved the way for new therapeutic approaches.
Published on
The Cancer Research Institute (CRI) has awarded the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology to Prof. Éric Vivier, holder of the Natural Killer (NK) Cell Chair of the Fondation Gustave Roussy. This distinction, one of the most prestigious in cancer immunology, recognizes his body of work, which has profoundly transformed the understanding of antitumor immunity and paved the way for new therapeutic approaches.
The William B. Coley Award honors researchers whose discoveries have had a lasting impact on the field of cancer immunology. The award will be presented to Prof. Éric Vivier on October 20, 2026, in New York. He will also deliver the Coley Lecture during the annual Society for Immunotherapy of Cancer (SITC) conference on November 8, 2026, in Phoenix, Arizona.
Professor of Immunology at Aix Marseille Université, hospital practitioner at Assistance Publique–Hôpitaux de Marseille (AP-HM), co-founder of the Marseille-Luminy Center of Immunology, and President of the Paris-Saclay Cancer Cluster (PSCC), Prof. Éric Vivier is one of the pioneers in the study of NK cells. For more than thirty years, his research has contributed to a better understanding of the essential role these cells play in recognizing and eliminating cancer cells.
At Gustave Roussy, Prof. Éric Vivier leads the Fondation Gustave Roussy Natural Killer (NK) Cell Chair, which explores the therapeutic potential of these cells in order to enhance their antitumor activity and develop new strategies aimed at strengthening the immune response against cancer.
NK Cells at the Heart of Immunotherapy
NK cells are white blood cells involved in innate immunity that can rapidly detect and eliminate cancer cells while sparing healthy cells. They also play a key role in activating other components of the immune response, particularly macrophages and T lymphocytes.
They have helped establish innate immunity as a cornerstone of modern immunotherapy and are now driving the development of new therapeutic approaches currently being evaluated in clinical trials.
Last news
-
Nuclear medicine: DART, a pioneering platform for the development of alpha therapy
Developed through a partnership between Gustave Roussy and the Paris-Saclay Cancer Cluster, the DART project aims to provide industry partners with a centre of excellence spanning preclinical, clinical and translational research to support the development of alpha therapy. This innovative nuclear medicine approach can destroy cancer cells more powerfully than standard approaches while reducing damage to surrounding healthy cells.
-
Gustave Roussy at the ESMO 2026 Congress
The European Society for Medical Oncology (ESMO) is holding its annual congress from 23 to 27 October in Madrid, Spain. This major international event provides oncologists and researchers from around the world with an opportunity to present the latest findings from clinical studies aimed at improving cancer care and deepening our understanding of the disease. Once again, this year, physicians and researchers from Gustave Roussy have contributed to several dozen studies that will be presented during the five-day congress.
-
5 questions with Dr François-Xavier Danlos about therapeutic cancer vaccines
Therapeutic cancer vaccines are making significant progress in clinical development. The ESMO Congress, which begins on 23 October, will provide an opportunity to learn about new data on a therapeutic vaccine against melanoma. However, there are major differences between vaccines traditionally used to prevent disease and therapeutic cancer vaccines. Dr François-Xavier Danlos, a medical oncologist in Gustave Roussy’s Drug Development Department and a specialist in immunotherapy development, explains.
-
ADCs: Two Landmark Publications in Cancer Cell and Nature Medicine Showcase Gustave Roussy's Expertise
In less than two months, researchers and clinicians from Gustave Roussy have contributed to two major publications on Antibody-Drug Conjugates (ADCs) in Cancer Cell and Nature Medicine. Together, these papers provide both a comprehensive overview of current knowledge and a strategic vision to accelerate the development of the next generation of these innovative therapies.
